Antibody-drug conjugates (ADCs) and emerging XDC modalities require tight control over chemistry, conjugation, analytics and regulatory readiness from the earliest stages. Download our two-page infosheet for an overview of Ardena’s integrated capabilities, spanning linker and payload chemistry, conjugation, clinical manufacturing and GLP bioanalysis.
